NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis → Will this AI Micro-Cap be Bigger than NVIDIA? (From Behind the Markets) (Ad) Free CVM Stock Alerts $1.25 -0.05 (-3.85%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.3050-Day Range$1.18▼$1.7252-Week Range$1.04▼$3.23Volume207,046 shsAverage Volume317,788 shsMarket Capitalization$67.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get CEL-SCI alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About CEL-SCI Stock (NYSE:CVM)CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More CVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVM Stock News HeadlinesJune 6, 2024 | businesswire.comDr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical AdvisorMay 22, 2024 | money.usnews.comCel-Sci Corp.May 21, 2024 | finance.yahoo.comCVM: Confirmatory Study ClarityMay 16, 2024 | businesswire.comCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsMay 8, 2024 | msn.comCEL-SCI gains as FDA greenlights confirmatory study for MultikineMay 8, 2024 | businesswire.comCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerApril 23, 2024 | businesswire.comCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsApril 16, 2024 | businesswire.comChannel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentApril 15, 2024 | finance.yahoo.comCVM: Parallel Engagement on Four FrontsApril 12, 2024 | msn.comScientists produce in vitro model of cell differentiation during early facial developmentApril 9, 2024 | msn.comResearchers discover two vesicle fusion mechanisms while studying vesicle movement in living cellsApril 6, 2024 | seekingalpha.comCVM CEL-SCI CorporationMarch 28, 2024 | msn.comCross-species insights: Study finds calcium link in plant and animal immunityMarch 19, 2024 | stockhouse.comCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 19, 2024 | finance.yahoo.comCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 11, 2024 | msn.comResearchers reveal a new mechanism that regulates intestinal stem cellsMarch 6, 2024 | businesswire.comCEL-SCI Corporation Issues Letter to ShareholdersFebruary 23, 2024 | finance.yahoo.comCVM Apr 2024 4.000 callFebruary 15, 2024 | finance.yahoo.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 15, 2024 | businesswire.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 13, 2024 | finance.yahoo.comCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockFebruary 12, 2024 | seekingalpha.comCel-Sci: Fabulous Story Stock Works To Pass Muster With FDAFebruary 9, 2024 | msn.comWhy CEL-SCI Corporation (CVM) Shares Are DivingFebruary 9, 2024 | finance.yahoo.comCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockFebruary 6, 2024 | stockhouse.comCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugSee More Headlines Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today6/17/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CVM CUSIPN/A CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-218.00% Return on Assets-98.53% Debt Debt-to-Equity Ratio0.63 Current Ratio1.67 Quick Ratio1.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book4.46Miscellaneous Outstanding Shares54,160,000Free Float46,545,000Market Cap$67.70 million OptionableOptionable Beta1.04 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Geert R. Kersten Esq. (Age 65)Chief Executive & Financial Officer, Treasurer and Director Comp: $702.79kMs. Patricia B. Prichep (Age 73)Senior VP of Operations & Corporate Secretary Comp: $295.18kDr. Eyal Talor Ph.D. (Age 68)Chief Scientific Officer Comp: $351.88kDr. Daniel H. Zimmerman Ph.D. (Age 83)Senior Vice President of Research & Cellular Immunology Comp: $46.08kMr. John Cipriano (Age 82)Senior Vice President of Regulatory Affairs Comp: $246.97kKey CompetitorsPoseida TherapeuticsNASDAQ:PSTXTenaya TherapeuticsNASDAQ:TNYACentury TherapeuticsNASDAQ:IPSCAdaptimmune TherapeuticsNASDAQ:ADAPMolecular PartnersNASDAQ:MOLNView All CompetitorsInsiders & InstitutionsVirtu Financial LLCSold 42,316 shares on 5/20/2024Ownership: 0.033%Tidal Investments LLCBought 13,891 shares on 5/17/2024Ownership: 0.026%Vanguard Group Inc.Bought 113,703 shares on 5/10/2024Ownership: 4.063%Geert R KerstenBought 30,000 shares on 5/8/2024Total: $41,700.00 ($1.39/share)Patricia B PrichepBought 8,000 shares on 5/8/2024Total: $11,120.00 ($1.39/share)View All Insider TransactionsView All Institutional Transactions CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed in 2024? CEL-SCI's stock was trading at $2.72 at the start of the year. Since then, CVM stock has decreased by 54.0% and is now trading at $1.25. View the best growth stocks for 2024 here. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) announced its quarterly earnings data on Thursday, May, 16th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). When did CEL-SCI's stock split? CEL-SCI's stock reverse split before market open on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.06%), CVI Holdings LLC (1.63%), Thoroughbred Financial Services LLC (0.11%), Virtu Financial LLC (0.03%), Chilton Capital Management LLC (0.03%) and Tidal Investments LLC (0.03%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, Patricia B Prichep, Peter R Young and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CVM) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.